Ziccum AB
Ziccum AB (publ) develops dry powder preparations of biological pharmaceuticals. It develops and commercializes LaminarPace, a spray drying technology that dries liquid biopharmaceuticals, such as vaccines or protein therapeutics into a particle engineered powder product. The company was incorporated in 2017 and is headquartered in Lund, Sweden.
Ziccum AB (ZICC) - Net Assets
Latest net assets as of September 2024: Skr2.52 Million SEK
Based on the latest financial reports, Ziccum AB (ZICC) has net assets worth Skr2.52 Million SEK as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr9.85 Million) and total liabilities (Skr7.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr2.52 Million |
| % of Total Assets | 25.6% |
| Annual Growth Rate | 30.9% |
| 5-Year Change | -49.99% |
| 10-Year Change | N/A |
| Growth Volatility | 226.84 |
Ziccum AB - Net Assets Trend (2017–2023)
This chart illustrates how Ziccum AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ziccum AB (2017–2023)
The table below shows the annual net assets of Ziccum AB from 2017 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | Skr8.58 Million | -70.70% |
| 2022-12-31 | Skr29.30 Million | -1.45% |
| 2021-12-31 | Skr29.73 Million | -18.28% |
| 2020-12-31 | Skr36.38 Million | +111.94% |
| 2019-12-31 | Skr17.17 Million | +43.11% |
| 2018-12-31 | Skr11.99 Million | +602.69% |
| 2017-12-31 | Skr1.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ziccum AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6267.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr2.30 Million | 26.81% |
| Other Components | Skr105.40 Million | 1227.87% |
| Total Equity | Skr8.58 Million | 100.00% |
Ziccum AB Competitors by Market Cap
The table below lists competitors of Ziccum AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WGELF
OTCGREY:WGELF
|
$305.35K |
|
IGEN Networks Corp
PINK:IGEN
|
$305.40K |
|
MGM RESORTS ITL
BE:MGG
|
$305.79K |
|
Adamas One Corp. Common Stock
PINK:JEWL
|
$305.86K |
|
CHIPOTLE MEXICAN
BE:C9F
|
$305.30K |
|
MITSUI ENGR & SHIP - Dusseldorf Stock Exchang
DU:MU1
|
$305.28K |
|
ROGERS COMM -B-
BE:RCIB
|
$305.27K |
|
ANTERIX INC. DL -0001
F:2X6
|
$305.14K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ziccum AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 29,301,000 to 8,584,000, a change of -20,717,000 (-70.7%).
- Net loss of 21,412,000 reduced equity.
- Other factors increased equity by 695,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-21.41 Million | -249.44% |
| Other Changes | Skr695.00K | +8.1% |
| Total Change | Skr- | -70.70% |
Book Value vs Market Value Analysis
This analysis compares Ziccum AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.40x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Skr0.63 | Skr0.25 | x |
| 2018-12-31 | Skr3.33 | Skr0.25 | x |
| 2019-12-31 | Skr2.85 | Skr0.25 | x |
| 2020-12-31 | Skr4.31 | Skr0.25 | x |
| 2021-12-31 | Skr2.69 | Skr0.25 | x |
| 2022-12-31 | Skr2.11 | Skr0.25 | x |
| 2023-12-31 | Skr0.62 | Skr0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ziccum AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -249.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -571.44%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.74x
- Recent ROE (-249.44%) is below the historical average (-83.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -30.38% | 0.00% | 0.00x | 1.02x | Skr-689.37K |
| 2018 | -38.11% | -2013.66% | 0.02x | 1.07x | Skr-5.77 Million |
| 2019 | -50.83% | -1334.10% | 0.04x | 1.07x | Skr-10.44 Million |
| 2020 | -47.67% | -346860.00% | 0.00x | 1.09x | Skr-20.98 Million |
| 2021 | -71.16% | -423120.00% | 0.00x | 1.24x | Skr-24.13 Million |
| 2022 | -97.11% | -167376.47% | 0.00x | 1.14x | Skr-31.38 Million |
| 2023 | -249.44% | -571.44% | 0.25x | 1.74x | Skr-22.27 Million |
Industry Comparison
This section compares Ziccum AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ziccum AB (ZICC) | Skr2.52 Million | -30.38% | 2.91x | $305.34K |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |